TP53 and colorectal cancer: The difference in anti-growth potency between the synthesized derivatives (compounds 1–8) and their parent compounds (Sal-A and -B) suggests a positive contribution of the ester chain at C-8 and C-9 and confirms the ability of STLs to inhibit colorectal cancer cell growth independently of p53 status.